Onesource Specialty Pharma Ltd

Onesource Specialty Pharma Ltd has announced changes in its Senior Management Personnel (SMP). Preeti Kalra, Head of Human Resources, has been designated as an SMP, effective July 24, 2026. Concurrently, Ravi Kumar, Global Head – Injectables/ Head of Corporate Strategy, Portfolio & SPO, has resigned from his position, also effective July 24, 2026. The company has provided disclosures as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including Ravi Kumar's resignation letter.

OneSource Specialty Pharma Ltd announced strong Q1FY27 results with revenue surging 37% year-on-year to ₹4,490 million and EBITDA growing 39% year-on-year to ₹1,233 million. This robust performance was driven by the commercial launch of semaglutide in Canada and India, new MSA contracts, and customer wins. EBITDA margins expanded to 27.5%. The company reaffirmed its FY28 guidance of $400 million in organic revenue with a 40% EBITDA margin. The CEO highlighted the upcoming commercial operations of a second cartridge line in Q2 and the addition of a new global biosimilar customer, underscoring the company's integrated CDMO capabilities and capacity expansion.

Onesource Specialty Pharma Ltd has announced changes in its Senior Management Personnel (SMP). Preeti Kalra, Head of Human Resources, has been designated as an SMP effective July 24, 2026. Concurrently, Ravi Kumar, Global Head – Injectables/Head of Corporate Strategy, Portfolio & SPO, has resigned from his position as SMP, also effective July 24, 2026. These changes are disclosed as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

OneSource Specialty Pharma (formerly Stelis Biopharma) turned its June quarter around on a consolidated basis, posting PAT of ₹25.0 Cr against a ₹0.19 Cr loss a year ago, on revenue from operations of ₹449.0 Cr, up 37.2% YoY and 4.9% sequentially. The swing is genuinely operational, not accounting-driven: profit before exceptional items and tax flipped to ₹24.6 Cr from a ₹1.5 Cr loss a year earlier, and operating EBITDA margin expanded to 27.5% (from 27.0% YoY and 21.5% in Q4 FY26). Management attributes the print to the commercial launch of semaglutide in Canada and India, new Master Services Agreement wins, and the addition of another global biosimilar customer to its biologics book. Two items qualify the headline profit. Reported consolidated PBT of ₹20.3 Cr is struck after a ₹4.30 Cr exceptional legal charge tied to the ongoing Prestige/Sputnik Light manufacturing arbitration at the Singapore International Arbitration Centre (Biolexis subsidiary), and reported PAT of ₹25.0 Cr actually exceeds PBT because of a net ₹0.47 Cr deferred-tax credit — so the bottom line flatters the operating result slightly. Standalone tells a stronger story (PAT ₹51.2 Cr, no exceptional item, nil tax), and the >2x gap to consolidated reflects loss-making subsidiaries and the legal charge that only appear at the group level; readers seeing ₹51 Cr elsewhere should note consolidated ₹25 Cr is the primary basis. Against guidance, the quarter is on-track: on the Q4 concall management promised strengthening sequential revenue and EBITDA growth through FY27 on the semaglutide ramp, and Q1 delivered both (revenue +4.9% QoQ, margin +600 bps QoQ). Consensus had modelled a final loss for FY26 with breakeven only nearing, so a Q1 group profit lands ahead of the Street's timeline. The concurrent developments fit the narrative — a Formycon AG biosimilar manufacturing partnership and a clean USFDA cGMP inspection support the capacity/demand story, while the Ravi Kumar resignation (Preeti Kalra designated SMP) is a governance change rather than a numbers driver. The key watch is whether the second cartridge line, due commercial in Q2, sustains the sequential ramp management is guiding to.

Onesource Specialty Pharma Ltd has announced that its Board of Directors will convene on July 24, 2026. The primary agenda item is to consider and approve the unaudited financial results, both standalone and consolidated, for the quarter ended June 30, 2026. Additionally, the company will address other business matters. In line with SEBI regulations, the trading window for designated persons will remain closed from July 1, 2026, and will reopen 48 hours after the financial results are disseminated.

OneSource Specialty Pharma Limited and Formycon AG have announced a strategic manufacturing partnership for biosimilars. Under this agreement, OneSource will act as a key manufacturing partner for Formycon, providing integrated Drug Substance (DS) and Drug Product (DP) manufacturing services from its facility in Bangalore. This collaboration aims to leverage Formycon's expertise in biosimilar development with OneSource's end-to-end biologics manufacturing capabilities to enhance global access to biosimilars. The partnership underscores a shared commitment to reliable, high-quality, and scalable manufacturing, with OneSource positioned to offer a sustainable and cost-effective model. Formycon brings a strong biosimilar portfolio and pipeline, while OneSource offers a comprehensive biologics platform and regulatory approvals from major authorities like the US FDA and EMA.

Onesource Specialty Pharma Limited has clarified that the delay in commercial supplies of Semaglutide announced by Dr. Reddy's Laboratories (DRL) will not have any material financial or operational impact on its business. The company highlighted its commitment to its partnership with DRL and stated it has sufficient demand from other customers, including for Canada. Onesource is also expanding its manufacturing capacities starting this quarter to meet future demand, including DRL's requirements once they are ready. The company remains focused on its growth plans and serving global customers.

Onesource Specialty Pharma Ltd announced that its Sterile Product Division facility in Bengaluru underwent a routine current Good Manufacturing Practices (cGMP) inspection by the United States Food and Drug Administration (USFDA). The inspection, which took place from June 22 to June 30, 2026, concluded with one observation. The company stated it will provide a comprehensive response to the FDA within the stipulated timeframe and will keep the stock exchanges informed of further developments.

Onesource Specialty Pharma Ltd has announced the closure of its trading window for the declaration of unaudited financial results for the quarter ended June 30, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will be shut from July 01, 2026, and will reopen 48 hours after the financial results are declared. The date of the board meeting to approve these results will be communicated separately. This measure is standard practice to prevent insider trading during sensitive financial reporting periods.

Onesource Specialty Pharma Ltd. has acknowledged the resignation of Prateek Gupta (SVP & Head – Technical Development), effective at the close of business hours on May 15, 2026. The company submitted the acknowledgement copy of the resignation letter to the Stock Exchanges, as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The resignation was initially intimated on May 13, 2026.